Boardroom Alpha
Boardroom Alpha
MATV · Current Report (Form 8-K) · Filed January 14, 2026

Mativ Holdings Inc — Current Report (Form 8-K)

Form
8-K
Filed
January 14, 2026
Period
Jan 14, 2026
Ticker
MATV
Accession
0001000623-26-000005
Boardroom Alpha · Filing insights

Former CFO Gregory Weitzel departs; Separation Agreement confirms severance under the Executive Severance Plan.

About Mativ Holdings Inc
Market cap
$452M
1Y TSR
+39.1%
3Y TSR
−15.2%
Board grade
C-
Sector
Basic Materials
CEO
Shruti Singhal
Last annual meeting: Apr 30, 2026 · View full Mativ Holdings Inc profile →
matv-20260114

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 14, 2026
Date of Report (Date of earliest event reported)

1-13948
(Commission file number)
MATIV HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware62-1612879
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
100 Kimball Place,Suite 600
Alpharetta,Georgia30009
(Address of principal executive offices)(Zip Code)

 
1-770-569-4229
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  Written communications pursuant to Rule 425 under the Securities Act. (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act. (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 par valueMATVNew York Stock Exchange

  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Separation Agreement with Former Chief Financial Officer

On December 16, 2025, Mativ Holdings, Inc. (the “Company”) filed a Current Report on Form 8-K with the U.S. Securities Exchange Commission (the “SEC”) announcing the departure of the Company’s former Chief Financial Officer, Gregory Weitzel, effective December 31, 2025. In connection with the previously announced departure of Mr. Weitzel, the Company and Mr. Weitzel entered into a Separation Agreement and General Waiver and Release (the “Separation Agreement”) on January 8, 2026 confirming the severance benefits and post-termination obligations pursuant to the Company’s Executive Severance Plan and the awards governing his outstanding equity awards, which includes a customary release of claims. The severance benefits to which Mr. Weitzel will be entitled pursuant to the Separation Agreement will be consistent with the severance benefits described under the caption “Potential Payments Upon Termination or Change of ControlTermination Not in Connection with a Change of Control” in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 21, 2025. The foregoing summary of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits are attached with this current report on Form 8-K:

Exhibit No.Description
10.1+
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
+ Indicates management compensatory plan or arrangement





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Mativ Holdings, Inc.
(Registrant)


By:/s/ Mark W. Johnson
Name:Mark W. Johnson
Title:Chief Legal and Administrative Officer
Date:January 14, 2026



From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Mativ Holdings Inc (MATV)

Reference

Frequently asked questions

When did Mativ Holdings Inc file this 8-K?
Mativ Holdings Inc (MATV) filed this Current Report (Form 8-K) with the SEC on January 14, 2026. The accession number assigned by EDGAR is 0001000623-26-000005.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Former CFO Gregory Weitzel departs; Separation Agreement confirms severance under the Executive Severance Plan. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Mativ Holdings Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Mativ Holdings Inc has filed under CIK 1000623, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer